Prophylactic and therapeutic vaccination with carrier‐bound Bet v 1 peptides lacking allergen‐specific T cell epitopes reduces Bet v 1‐specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Issue 2 (22nd January 2014)

• Record Type: Journal Article
• Authors: Linhart, B.; Narayanan, M.; Focke‐Tejkl, M.; Wrba, F.; Vrtala, S.; Valenta, R.
• Is Part Of: Clinical & experimental allergy. Volume 44:Issue 2(2014:Feb.)
• Page Start: 278
• Page End: 287
• Publication Date: 2014-01-22
• Subjects: Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.12216
• Languages: English
• ISSNs: 0954-7894

Abstract

<abstract abstract-type="main" id="cea12216-abs-0001"> <title>Summary</title> <sec id="cea12216-sec-0001" sec-type="section"> <title>Background</title> <p>Vaccines consisting of allergen‐derived peptides lacking IgE reactivity and allergen‐specific T cell epitopes bound to allergen‐unrelated carrier molecules have been suggested as candidates for allergen‐specific immunotherapy.</p> </sec> <sec id="cea12216-sec-0002" sec-type="section"> <title>Objective</title> <p>To study whether prophylactic and therapeutic vaccination with carrier‐bound peptides from the major birch pollen allergen Bet v 1 lacking allergen‐specific T cell epitopes has influence on Bet v 1‐specific T cell responses.</p> </sec> <sec id="cea12216-sec-0003" sec-type="section"> <title>Methods</title> <p>Three Bet v 1‐derived peptides, devoid of Bet v 1‐specific T cell epitopes, were coupled to KLH and adsorbed to aluminium hydroxide to obtain a Bet v 1‐specific allergy vaccine. Groups of BALB/c mice were immunized with the peptide vaccine before or after sensitization to Bet v 1. Bet v 1‐ and peptide‐specific antibody responses were analysed by ELISA. T cell and cytokine responses to Bet v 1, KLH, and the peptides were studied in proliferation assays. The effects of peptide‐specific and allergen‐specific antibodies on T cell responses and allergic lung inflammation were studied using specific antibodies.</p> </sec> <sec id="cea12216-sec-0004" sec-type="section"> <title>Results</title> <p>Prophylactic and therapeutic vaccination with carrier‐bound Bet v 1 peptides induced a Bet v 1‐specific IgG antibody response without priming/boosting of Bet v 1‐specific T cells. Prophylactic and therapeutic vaccination of mice with the peptide vaccine induced Bet v 1‐specific antibodies which suppressed Bet v 1‐specific T cell responses and allergic lung inflammation.</p> </sec> <sec id="cea12216-sec-0005" sec-type="section"> <title>Conclusion and Clinical Relevance</title> <p>Vaccination with carrier‐bound allergen‐derived peptides lacking allergen‐specific T cell epitopes induces allergen‐specific IgG antibodies which suppress allergen‐specific T cell responses and allergic lung inflammation.</p> </sec> </abstract>